Erasca, Inc.
13 articles with Erasca, Inc.
-
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
7/20/2021
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its initial public offering of 21,562,500 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 2,812,500 additional shares, at an initial public offering price of $16.00 per share
-
Erasca Announces Pricing of Upsized Initial Public Offering
7/16/2021
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its upsized initial public offering of 18,750,000 shares of common stock at an initial public offering price of $16.00 per share
-
Erasca Expands Leadership Team with Key Appointments - May 27, 2021
5/27/2021
Erasca, a clinical-stage precision oncology company whose mission is to erase cancer and that is singularly focused on advancing therapies for patients with RAS/MAPK pathway-driven cancers, announced the expansion of its leadership team with key hires in finance, business development, operations, legal, regulatory, manufacturing, clinical pharmacology and data science.
-
Erasca Appoints Bihua Chen and Julie Hambleton, M.D., to its Board of Directors
3/29/2021
Ms. Chen, portfolio manager at Cormorant Asset Management, and Dr. Hambleton, a physician-turned-biotech executive, bring decades of experience to their new roles
-
Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient
1/6/2021
Successful additions of ERAS-601 and ERAS-007, potential best-in-class inhibitors of SHP2 and ERK, respectively, enable “MAPK Clamp” approach to shut down RAS/MAPK pathway Erasca doses first patient in FLAGSHP-1 study, Erasca’s first clinical trial
-
BioSpace Movers & Shakers, Aug. 28
8/28/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Erasca Recruits Michael Varney, Ph.D., as Chairman of Research & Development and Scientific Advisory Board Member
8/24/2020
Erasca, a company whose mission is to erase cancer, today announced that Michael Varney, Ph.D., has joined the organization’s Scientific Advisory Board (SAB) and will also serve as Chairman of Research & Development (R&D). In these roles, Dr. Varney will help advance Erasca’s drug discovery portfolio by providing strategic input on portfolio o
-
BioSpace Movers & Shakers, June 19
6/19/2020
Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Erasca Expands Leadership Team with Key Regulatory and Clinical Appointments
6/16/2020
Erasca, a company whose mission is to erase cancer, today announced the expansion of its leadership team with the appointment of Bao Truong as vice president of regulatory affairs and David Luo as vice president of clinical research and operations. “We are delighted to continue attracti
-
Erasca Raises $200 Million Series B Financing
4/27/2020
Erasca, a company whose mission is to erase cancer, today announced the completion of a $200 million Series B financing round co-led by ARCH Venture Partners and Cormorant Asset Management. New investors participating in this financing inc
-
Erasca Announces Key Leadership Team Appointments and Recruits World-Class Research and Development Advisory Board
8/22/2019
Erasca, a company dedicated to advancing exceptional scientific approaches to erase cancer, today announced the promotion of Gary Yeung, CFA, to chief operating and financial officer, as well as the appointment of David Chacko, M.D., to chief business officer. Les Brail, Ph.D., has been appointed vice president of clinical development, and Karen Gilmore, CPA, has been appointed vice president of finance.
-
Erasca™ Announces Series A Extension, Bringing Total Round to $64 Million
3/5/2019
Proceeds of financing will fuel corporate development efforts and further buildout of artificial intelligence platform to accelerate drug discovery in bold mission to erase cancer
-
Days before Christmas, three new companies decided to strip away the wrapping paper and unveil themselves to the world. Each of the companies launched with millions of dollars raised through a Series A financing round.